Key result
Resuming anticoagulation >4 weeks post-ICH is preferred by ~58% of surveyed experts.
Why the study?
Patients with primary or metastatic brain tumors who develop spontaneous intracranial hemorrhage on antithrombotic therapy pose competing risks of recurrent hemorrhage and thrombosis, yet data describing multidisciplinary expert practice patterns are limited.
How do neurosurgeons and anticoagulation experts manage anticoagulation resumption after spontaneous intracranial hemorrhage in patients with brain tumors?
Cross-Sectional (n=34)
Yes
How do neurosurgeons and anticoagulation experts manage anticoagulation resumption after spontaneous intracranial hemorrhage in patients with brain tumors?
Expert management of anticoagulation resumption after intracranial hemorrhage in brain tumor patients favors waiting over 4 weeks and switching agents, though neurosurgeons and hematologists differ significantly on prioritizing neurologic status versus thrombotic risk scores and cancer prognosis.
Answers are grounded in this paper and cite their sources.
Indication for antithrombotic therapy primarily guides resumption after brain tumor hemorrhage; leaves optimal timing and agents open for prospective study.
Background Patients with primary or metastatic brain tumors who develop spontaneous intracranial hemorrhage while receiving antithrombotic therapy present a major clinical challenge due to competing risks of recurrent hemorrhage and thrombosis. Despite multidisciplinary involvement in management, data describing expert practice patterns are limited. Methods A multidisciplinary team developed a survey evaluating management strategies for spontaneous intracranial hemorrhage (ICH) in patients with brain tumors receiving antithrombotic therapy. Anticoagulation experts were identified through hematology guideline authorship, collaboration with the International Society on Thrombosis and Haemostasis (ISTH) Committee on Cancer-Associated Thrombosis, and recruitment at the ISTH 2025 Congress. Neurosurgeons were identified through recent high-impact neuro-oncology research publications and recruitment at the Congress of Neurological Surgeons 2025 Annual Meeting. Between June and October 2025, participants completed a 21-question survey; anticoagulation experts additionally reviewed four clinical vignettes. Ninety-four invitations were sent to hematology experts, with a 24.5% response rate, and 129 invitations were sent to neurosurgeons, with an 11% response rate. Descriptive and comparative statistical analyses were performed. Results Forty experts partially completed the survey, including 34 respondents with substantial completion (13 neurosurgeons, 21 anticoagulation experts). Neurosurgeons, hematologists, and critical care providers were the top specialties responsible for decision-making. Indication for antithrombotic therapy was considered the most important factor guiding anticoagulation resumption (73%). Resumption beyond four weeks after hemorrhage was the preferred timeframe (58%). Most respondents favored changing the antithrombotic agent (61%) and obtaining interval neuroimaging after resumption. Compared with anticoagulation experts, neurosurgeons were less likely to consider cancer prognosis (p = 0.0022) or CHADS2VAS2C scores (p = 0.0014) and more likely to prioritize neurologic status (p = 0.0107). Conclusions Management of anticoagulation after spontaneous ICH in brain tumors demonstrates both areas of consensus and substantial specialty-specific variability. These findings highlight the need for prospective, multidisciplinary studies and collaborative guideline development to optimize care among this high risk neuro-oncology patient population.
No takes yet. Share an insight, caveat, or question.
Tripathy et al. (2026) conducted a cross-sectional in Spontaneous intracranial hemorrhage in patients with primary or metastatic brain tumors receiving antithrombotic therapy (n=34). Neurosurgeon specialty practice patterns vs. Anticoagulation expert specialty practice patterns was evaluated on Expert practice patterns and factors guiding anticoagulation resumption after spontaneous intracranial hemorrhage (p=0.0022). Resuming anticoagulation >4 weeks post-ICH was preferred by 58% of experts, with neurosurgeons less likely than anticoagulation experts to consider CHADS2VAS2C scores.
Synapse has enriched 10 related papers. Consider them for comparative context: